Pharmaceuticals

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

Moving beyond hype, ArisGlobal's record growth and enterprise adoption of its NavaX AI show the pharmaceutical industry is now operationalizing AI at scale.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Kye Pharma brings SLENYTO®, a first-of-its-kind prescription sleep aid, to Canada, offering relief to children with ASD and SMS and their families.

As regulations tighten, Americhem unveils new polymers designed to help medical device makers navigate PFAS bans and enhance device traceability.

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

The first-ever Wegovy pill is now available via telehealth platform Ro, offering a cash-pay option that could revolutionize access to weight loss drugs.

Aptar's 'Beat the Blink' technology, in partnership with Bausch + Lomb, promises to solve the age-old problem of inaccurate eye drop dosing.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

The deal completes insitro’s TherML platform, integrating physics-informed AI to design better drugs faster by solving efficacy and manufacturing hurdles at once.

Private equity firm Five Arrows makes a majority investment in Blue Mountain to fuel AI innovation, product growth, and European expansion for its compliance software.

AI firm Owkin is leveraging NVIDIA's powerful computing to build a 'Biological Artificial Super Intelligence,' aiming to revolutionize drug discovery.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.

As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

Following a successful three-year transformation, B-FLEXION acquires full ownership of Radius Health, betting big on its blockbuster osteoporosis drug TYMLOS®.